Kanghong’s KH617 Receives Orphan Drug Designation for Glioblastoma
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving an Orphan Drug...
Drug
Luye Pharma’s BA2101 Begins Phase I Clinical Trial for Allergic Diseases
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
CDE Accepts Clinical Trial Filing for Ranok’s First-in-Class BRD4 Degradation Drug RNK05047
The Center for Drug Evaluation (CDE) website indicates that a clinical trial filing for RNK05047,...
Junshi Biosciences and Coherus Report Positive JUPITER-02 Trial Results for NPC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) and its US partner Coherus BioSciences...
Hengrui Pharmaceuticals Gains NMPA Approval for SHR-A1921 Clinical Study
Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving the go-ahead from the National Medical Products...
Zelgen’s ZG2001 and ZG0895 Clinical Trials Approved by NMPA
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that separate clinical trial filings for...
Innovent Biologics Initiates Phase II Study for IBI311 in Thyroid-Associated Ophthalmopathy
China-based Innovent Biologics Inc., (HKG: 1801) has announced the first patient dosing in a Phase...
Kangtai Biological Begins Phase I Trial for Tetravalent Influenza Vaccine
China-based Shenzhen Kangtai Biological Products Co., Ltd (SHE: 300601) has announced the first subject enrollment...
Jiangsu Recbio Completes First Tranche Enrollment for Shingles Vaccine REC610
China-based Jiangsu Recbio Technology Co., Ltd has announced the completion of the first tranche of...
Beijing Wantai Initiates Phase I Study for 20-Valent Pneumonia Vaccine
China-based Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392) has announced the initiation and...
Gracell Biotechnologies Gains IND Approval for GC012F in China
Gracell Biotechnologies has reported receiving Investigational New Drug (IND) approval from the Center for Drug...
RemeGen Gains NMPA Approval for RC48 and Pyrotinib Clinical Study
China-based RemeGen Ltd (HKG: 9995) has announced receiving the go-ahead from the National Medical Products...
Clover Biopharmaceuticals Administers First Dose of COVID-19 Vaccine SCB-2019 in Zhejiang
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has announced the first jab of its COVID-19 vaccine...
CSPC Pharmaceutical Licenses ADC SYS6002 to Corbus Pharmaceuticals
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced a licensing agreement with Massachusetts-based Corbus...
Luye Pharma Initiates Phase I Study for BA1106, a CD25 Monoclonal Antibody
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase...
Zelgen’s ZGGS15 Accepted for NMPA Review as First Global BsAb Filing
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for...
Kintor’s GT20029 Shows Positive Results in US Phase I Study for AGA and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I...
Hengrui’s HER2-Targeted ADC SHR-A1811 Aims for Breakthrough Designation
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug...
EOC Pharma’s CDK7 Inhibitor EOC237 Accepted for CDE Review
EOC Pharma, a biotech operating out of the US and China, has announced that a...
Joincare’s Generic Seretide Accepted for NMPA Review
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing...